Study of Patritumab Deruxtecan in Participants With Gastrointestinal Cancers (MK-1022-011) (HERTHENA-PanTumor02)

Clinical trial NCT06596694 · RECRUITING

Trial details

NCT number: NCT06596694
Sponsor: Merck Sharp & Dohme LLC
Status: RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Gastrointestinal Cancer

Start date: 2024-11-03
Primary completion: 2028-12-07
Enrollment: 180

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.